title: Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
abstract: BACKGROUND
  Platinum-based concurrent chemoradiotherapy (CCRT) is a standard treatment for locally advanced unresectable non-small cell lung cancer (NSCLC). The determination of parameters that may predict the result of the treatment has strong clinical implications.
  
  
  METHODS
  Pretreatment tumor biopsy specimens from 39 patients with locally advanced NSCLC (stage IIIA: 5, stage IIIB: 34) were analyzed for p53, Bcl-2, Bax and ERCC1 expression by immunohistochemistry. All patients were treated with cisplatin-based CCRT. Twenty-four patients received induction chemotherapy followed by CCRT (60Gy/30 fractions, 6mg/m(2) of cisplatin daily). The most commonly administered induction chemotherapy regimen was VIP (etoposide, ifosfamide, cisplatin; 20 patients). Fifteen patients received the same CCRT without induction chemotherapy.
  
  
  RESULTS
  High expression of p53, Bcl-2, Bax and ERCC1 was observed in 15 (38%), 19 (49%), 17 (44%) and 12 (31%) patients, respectively. High expression of Bcl-2 was significantly associated with longer survival duration (20 months vs. 9 months, P=0.008) and better response to the treatment (74% vs. 30%, P=0.01). In multivariate analysis, Bcl-2 expression was the only significant independent prognostic factor of overall survival (P=0.007) among the pretreatment patients characteristics.
  
  
  CONCLUSIONS
  High expression of Bcl-2 may be a useful prognostic factor in locally advanced NSCLC patients treated with cisplatin-based CCRT.
authors: Department of Hematology-Oncology, Ajou University School of Medicine, Suwon 443-721, Republic of Korea.
authors: Seong Hyun
authors: SH
authors: Jeong
authors: Jae Ho
authors: JH
authors: Jung
authors: Jae Ho
authors: JH
authors: Han
authors: Jang Hee
authors: JH
authors: Kim
authors: Yong-Won
authors: YW
authors: Choi
authors: Hyun Woo
authors: HW
authors: Lee
authors: Seok Yun
authors: SY
authors: Kang
authors: Yoon Ho
authors: YH
authors: Hwang
authors: Mi Sun
authors: MS
authors: Ahn
authors: Jin-Hyuk
authors: JH
authors: Choi
authors: Young Taek
authors: YT
authors: Oh
authors: Mison
authors: M
authors: Chun
authors: Seunghee
authors: S
authors: Kang
authors: Kwang Joo
authors: KJ
authors: Park
authors: Sung Chul
authors: SC
authors: Hwang
authors: Seung Soo
authors: SS
authors: Sheen
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D018450:Disease Progression; D004720:Endonucleases / Q000235:genetics / Q000378:metabolism; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism*; D018714:Radiotherapy, Adjuvant; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism; D051028:bcl-2-Associated X Protein / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein; C071447:ERCC1 protein, human; D004720:Endonucleases; D002945:Cisplatin